Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it?

Baffy, Gyorgy; Bosch, Jaime (2022). Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it? Journal of hepatology, 76(2), pp. 458-463. Elsevier 10.1016/j.jhep.2021.09.029

Text 1-s2.0-S0168827821020900-main.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (652kB)

Clinical and experimental advances related to the detection, magnitude and pathobiology of subclinical portal hypertension in non-alcoholic fatty liver disease (NAFLD), primarily observed in the presence of non-alcoholic steatohepatitis (NASH), prompt us to revisit current disease paradigms. Hepatic venous pressure gradient (HVPG) has been reported to underestimate portal pressure in NASH-related cirrhosis, while inaccuracy is more likely in non-cirrhotic livers, indicating a potential need for new and preferably non-invasive methods of measurement. Although clinically significant portal hypertension (HVPG ≥10 mmHg) retains its prognostic significance in NASH, subclinical portal hypertension (HVPG 6.0-9.5 mmHg) has been repeatedly detected in patients with NAFLD in the absence of cirrhosis or even significant fibrosis whereas the impact of these findings on disease outcomes remains unclear. Mechanocrine signalling pathways in various types of liver cell reveal a molecular basis for the adverse effects of subclinical portal hypertension and suggest a bidirectional relationship between portal pressure and fibrosis. These findings may guide efforts to improve risk assessment and identify novel therapeutic targets in NAFLD.

Interest & Impact

Downloads

1 since deposited on 10 Jan 2022
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item